Cargando…
Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair
Breast carcinomas commonly carry mutations in the tumor suppressor p53, although therapeutic efforts to target mutant p53 have previously been unfruitful. Here we report a selective combination therapy strategy for treatment of p53 mutant cancers. Genomic data revealed that p53 mutant cancers exhibi...
Autores principales: | Zonneville, Justin, Wang, Moyi, Alruwaili, Mohammed M., Smith, Brandon, Melnick, Megan, Eng, Kevin H., Melendy, Thomas, Park, Ben Ho, Iyer, Renuka, Fountzilas, Christos, Bakin, Andrei V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275734/ https://www.ncbi.nlm.nih.gov/pubmed/34253820 http://dx.doi.org/10.1038/s42003-021-02370-0 |
Ejemplares similares
-
TAK1 signaling regulates p53 through a mechanism involving ribosomal stress
por: Zonneville, Justin, et al.
Publicado: (2020) -
TGF-β signaling promotes tumor vasculature by enhancing the pericyte-endothelium association
por: Zonneville, Justin, et al.
Publicado: (2018) -
Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications
por: Gupta, Medhavi, et al.
Publicado: (2019) -
Tumor p38MAPK signaling enhances breast carcinoma vascularization and growth by promoting expression and deposition of pro-tumorigenic factors
por: Limoge, Michelle, et al.
Publicado: (2017) -
Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer
por: Fountzilas, Elena, et al.
Publicado: (2019)